The efficacy of Salvage Autologous Stem Cell Transplant for Patients With Multiple Myeloma Who Received Maintenance Therapy Post an Initial Transplant

被引：0
|
作者：
King, Justin [1 ]
Fiala, Mark [1 ]
Kohnen, Daniel [1 ]
Stockerl-Goldstein, Keith [1 ]
Wildes, Tanya [1 ]
Vij, Ravi [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 01期
关键词：
D O I：
10.1016/j.clml.2017.03.127
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS-125
引用
收藏
页码：E70 / E71
页数：2
相关论文
共 50 条
  • [21] Salvage autologous stem cell transplant is an effective regimen for relapsed multiple myeloma
    Gertz, Morie A.
    Lacy, Martha Q.
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2096 - 2097
  • [22] Role of Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma: Lessons for Cancer Therapy
    Kyle, Robert A.
    MAYO CLINIC PROCEEDINGS, 2011, 86 (05) : 419 - 420
  • [23] Impact of Maintenance Therapy on Nature of First Relapse in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplant
    Martin, Petra
    Ye, Rebecca
    Kolk, Merle
    Ferrari, Nicole
    Caimi, Paolo
    Metheny, Leland
    Driscoll, James
    de Lima, Marcos
    Malek, Ehsan
    BLOOD, 2018, 132
  • [24] Maintenance Therapy after Autologous Stem Cell Transplant Is Associated with Less Biochemical Relapse in Multiple Myeloma Patients
    Ye, Rebecca
    Martin, Petra
    Caimi, Paolo
    Kolk, Merle
    Metheny, Leland
    de Lima, Marcos
    Malek, Ehsan
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [25] CANADIAN COST ANALYSIS COMPARING MAINTENANCE THERAPY WITH BORTEZOMIB VERSUS LENALIDOMIDE FOR PATIENTS WITH MULTIPLE MYELOMA POST AUTOLOGOUS STEM CELL TRANSPLANT
    LeBlanc, R.
    Hollmann, S.
    Tay, J.
    JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2016, 23 (01): : E103 - E113
  • [26] Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma
    Shah, Jatin J.
    Baladandayuthapani, Veera
    Weber, Donna M.
    Thomas, Sheeba K.
    Alexanian, Raymond
    Wang, Michael
    Qazilbash, Muzaffar H.
    Champlin, Richard E.
    Shah, Nina
    Bashir, Qaiser
    Popat, Uday R.
    Nieto, Yago
    Ahmed, Sairah
    Parmar, Simrit
    Orlowski, Robert Z.
    BLOOD, 2013, 122 (21)
  • [27] RETROSPECTIVE REVIEW OF DPACE THERAPY AS A SALVAGE REGIMEN IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT
    Snider, J. N.
    Stelts, S. D.
    Awan, M.
    Raza, M.
    Goorha, S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S295 - S296
  • [28] Demographic Patterns and Outcomes of Multiple Myeloma Patients Received Autologous Stem Cell Transplant: A Nationwide Analysis
    Thalambedu, Nishanth
    Atodaria, Kuldeepsinh
    Fidler, Christian Joseph
    BLOOD, 2022, 140 : 13210 - 13211
  • [29] Rituximab maintenance therapy post autologous stem cell transplant (ASCT)
    Rice, R. D.
    Moskowitz, C. H.
    EJC SUPPLEMENTS, 2005, 3 (02): : 284 - 284
  • [30] Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma
    Rath, Carolyn
    Yoo, Claude
    Cheplowitz, Halle
    Lo, Mimi
    Young, Rebecca
    Guglielmo, Julie
    Saunders, Ila M.
    Banerjee, Rahul
    Young, Richard
    Kumar, Anupama
    Chung, Alfred
    Rosenberg, Aaron Seth
    Costello, Caitlin
    Fine, Jeffrey
    Wilson, Machelle
    Patel, Nimish
    Banez, Marisela Tan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (07) : 1715 - 1724
12345